Literature DB >> 15756753

Iressa failure raises fears about accelerated approvals.

Simon Frantz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15756753     DOI： 10.1038/nrd1649

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.

Authors:  Wei Feng; Xi Chen; Shao-Xing Guan; Hong-Lian Ruan; Yan Huang; Hui-Zhen Zhang; Yun-Peng Yang; Wen-Feng Fang; Hong-Yun Zhao; Wei Zhuang; Shuang Xin; You-Hao Chen; Fei Wang; Yue Gao; Min Huang; Xue-Ding Wang; Li Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-11-04       Impact factor: 7.169
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.